Gilead Sciences, Inc. provides an annual donation of $1.1 million, for an initial period of five years, to the Institute of Organic Chemistry and Biochemistry (IOCB) for the establishment of Gilead Sciences & IOCB Research Centre (GSRC). The establishment of the GSRC recognizes the Gilead continued partnership with IOCB and allows for expanded research efforts.
The donation is used to establish and support the GSRC, which consist of selected research groups led by the scientists at IOCB. Gilead and IOCB also established the Gilead Distinguished Chair in Medicinal Chemistry. Prof. Antonin Holy of the IOCB is the first to hold the position of Distinguished Chair and will continue to lead research efforts in nucleoside and nucleotide drug discovery. The donation allows IOCB funding the prestigious Gilead Fellowship in Medicinal Chemistry for post-doctoral visitors and the Gilead Stipend for Ph.D. students.
Gilead and IOCB also entered into a separate arrangement through which Gilead will provide patent services to the IOCB.
Gilead’s commitment to patients suffering from life-threatening diseases is one shared with colleagues at the IOCB, with whom we have enjoyed a longstanding relationship. In 1991 and 1992, Gilead entered into license agreements with IOCB and the Rega Institute in Leuven, Belgium that cover a number of nucleotide analogue compounds, including cidofovir, tenofovir and adefovir. Since that time, three of these compounds have been successfully developed and are improving the quality of life for patients around the globe: Vistide for the treatment of CMV retinitis in patients with AIDS, Viread for the treatment of HIV and Hepsera for the treatment of chronic hepatitis B.